Sterne, Kessler, Goldstein & Fox
Bill Flanigen is a seasoned professional in the legal field, currently serving as the Manager of the PTO Litigation Team at Sterne, Kessler, Goldstein & Fox since October 2013, where supervision of paralegals and project assistants focused on litigation at the Patent Trial and Appeal Board is a primary responsibility. Previously, Bill held the position of Senior Paralegal, leading a team in patent office litigation and prosecution related to software and hardware, and began career as a Paralegal assisting in similar capacities. Experience extends to Merrill Corporation as an office-support Clerk, and earlier roles include editorial and research internships at Carolina Journal and Reason Magazine. Bill's foundational work includes a Library Assistant position at Gelman Library while completing a BA in History and Philosophy at The George Washington University. Additional internships at the ACLU involved public policy research and advocacy related to prison policy.
This person is not in any offices
Sterne, Kessler, Goldstein & Fox
Sterne, Kessler, Goldstein & Fox is an intellectual property specialty firm dedicated exclusively to the protection, transfer and enforcement of IP rights for their clients. Their team of attorneys, registered patent agents, students and technical specialists include some of the country's most respected practitioners of intellectuall property law. Most of their professionals hold an advanced-level degree, including more than 50 with a doctorate in science or engineering. Teaming with their IP professionals is a dynamic and extraordinarily capable team of managers and staff in a work environment with robust technical platforms, protocols and systems for the highest levels of efficiency in delivering a full suite of services to clients.Their client base includes developing and established companies, venture capital firms, individual entrepreneurs and universities — from bleeding-edge technology fields, like carbon footprint technologies, pharmacogenomics, nanomedicine and biofuels to next-generation electronics and other consumer products.